SC 13G/A

Names of Reporting Persons

The Carlyle Group Inc.

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Delaware

SC 13G/A 1 d429415dsc13ga.htm SC 13G/A SC 13G/A

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Vaxcyte, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

92243G108

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 92243G108		Schedule 13G		Page 1 of 16


CUSIP No. 92243G108		Schedule 13G		Page 2 of 16


CUSIP No. 92243G108		Schedule 13G		Page 3 of 16


CUSIP No. 92243G108		Schedule 13G		Page 4 of 16


CUSIP No. 92243G108		Schedule 13G		Page 5 of 16


CUSIP No. 92243G108		Schedule 13G		Page 6 of 16


CUSIP No. 92243G108		Schedule 13G		Page 7 of 16


CUSIP No. 92243G108		Schedule 13G		Page 8 of 16


CUSIP No. 92243G108		Schedule 13G		Page 9 of 16


CUSIP No. 92243G108		Schedule 13G		Page 10 of 16


CUSIP No. 92243G108		Schedule 13G		Page 11 of 16

ITEM 1.

(a) Name of Issuer:

Vaxcyte, Inc. (the “Issuer”).

(b)

Address of Issuer’s Principal Executive Offices:

825 Industrial Road, Suite 300, San Carlos, CA 94070

ITEM 2.

(a) Name of Person Filing:

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

The Carlyle Group Inc.

Carlyle Holdings I GP Inc.

Carlyle Holdings I GP Sub L.L.C.

Carlyle Holdings I L.P.

CG Subsidiary Holdings L.L.C.

TC Group, L.L.C.

Carlyle Investment Management L.L.C.

Carlyle Genesis UK LLC

Abingworth LLP

Abingworth Bioventures VI LP

(b)

Address or Principal Business Office:

The principal business address of each of Abingworth LLP and Abingworth Bioventures VI LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.

(c)

Citizenship of each Reporting Person is:

Each of Abingworth LLP and Abingworth Bioventures VI LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

(d)

Title of Class of Securities:

Common Stock, par value $0.001 per share (“Common Stock”).

(e)

CUSIP Number:

92243G108


CUSIP No. 92243G108		Schedule 13G		Page 12 of 16

ITEM 3.

Not applicable.

ITEM 4.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2022, based upon 79,372,477 shares of Common Stock outstanding, which includes (i) 79,320,810 shares of Common Stock outstanding as of December 20, 2022, as disclosed in the Issuer’s registration statement on Form S-3 filed with the Securities and Exchange Commission on December 22, 2022 and (ii) 51,667 shares of Common Stock issuable upon exercise of stock options that may be deemed to be beneficially owned by the reporting person and which are exercisable or will be exercisable within 60 days of the date of this filing.


Reporting Person	Amount beneficially owned		Percent of class			Sole power to vote or to direct the vote		Shared power to vote or to direct the vote		Sole power to dispose or to direct the disposition		Shared power to dispose or to direct the disposition
The Carlyle Group Inc.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Carlyle Holdings I GP Inc.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Carlyle Holdings I GP Sub L.L.C.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Carlyle Holdings I L.P.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
CG Subsidiary Holdings L.L.C.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
TC Group, L.L.C.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Carlyle Investment Management L.L.C.		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Carlyle Genesis UK LLC		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Abingworth LLP		2,070,724		2.6	%		0		2,070,724		0		2,070,724
Abingworth Bioventures VI LP		2,070,724		2.6	%		0		2,070,724		0		2,070,724

The shares of Common Stock reported herein include (i) 2,019,057 shares of Common Stock held of record by Abingworth Bioventures VI LP and (ii) 51,667 shares of Common Stock underlying stock options exercisable within 60 days of the date of this filing that may be deemed to be beneficially owned by Abingworth Bioventures VI LP.

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C.,


CUSIP No. 92243G108		Schedule 13G		Page 13 of 16

which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VI LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VI LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VI LP, but each disclaims beneficial ownership of such securities.

ITEM 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following: ☒

ITEM 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

ITEM 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

ITEM 9.

Notice of Dissolution of Group.

Not applicable.

ITEM 10.

Certification.

Not applicable.


CUSIP No. 92243G108		Schedule 13G		Page 14 of 16

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2023


The Carlyle Group Inc.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Chief Financial Officer

Carlyle Holdings I GP Inc.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Managing Director and Chief Financial Officer

Carlyle Holdings I GP Sub L.L.C.
By: Carlyle Holdings I GP Inc., its sole member

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Managing Director and Chief Financial Officer

Carlyle Holdings I L.P.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Managing Director

CG Subsidiary Holdings L.L.C.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Managing Director

TC Group, L.L.C.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Managing Director


CUSIP No. 92243G108		Schedule 13G		Page 15 of 16


Carlyle Investment Management L.L.C.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Chief Financial Officer

Carlyle Genesis UK LLC
By: Carlyle Investment Management L.L.C., its sole member

By:		/s/ Anne Frederick, attorney-in-fact
Name:		Curtis L. Buser
Title:		Chief Financial Officer

Abingworth LLP

By:		/s/ John Heard
Name:		John Heard
Title:		Authorized Signatory

Abingworth Bioventures VI LP

By:		/s/ John Heard
Name:		John Heard
Title:		Authorized Signatory


CUSIP No. 92243G108		Schedule 13G		Page 16 of 16

LIST OF EXHIBITS


Exhibit No.		Description

24		Power of Attorney.

99		Joint Filing Agreement.

SEC Form SC 13G/A filed by Vaxcyte Inc. (Amendment)